Автореферат и диссертация по медицине (14.00.14) на тему:Роль мутации гена СНЕК2 в формировании наследственной предрасположенности к развитию рака яичника

Введение

Глава 1. Обзор литературы

Глава 2. Материалы и методы

Глава 3. Результаты

1. Аксель Е.М., Давыдов М.И. Статистика заболеваемости и смертности от злокачественных новообразований в 2000г. // Злокачественные новообразования в России и странах СНГ в 2000г.-М.,2002.-с.85-106.

2. Аксель E.H. Злокачественные новообразования в странах СНГ // 3 съезд онкологов. «Эпидемиология злокачественных новообразований, организация онкологической помощи».-№24.-с. 1095-1102.

3. Аксель E.H., Бармина Н.М., Трапезников H.H. Заболеваемость и смертность от злокачественных новообразований населения России // 1996,-Онкологический научный центр им. H.H. Блохина. М.

4. Акуленко JI.B., Брюзгин В.В., Жорданиа К.И. и соавт. Медико-генетический подход к ранней диагностике и профилактике рака // Вопр. онкол.-1991.-Т.37.-№2.-с.211-215.

5. Акуленко JI.B., Жорданиа К.И., Козаченко В.П. и соавт. Клинические особенности семейного рака органов женской репродуктивной системы //Материалы 5-го Всероссийского съезда онкологов. Казань-2000.-Т.2.-с.440-442.

6. Алексина JI.A., Ганина К.П., Осинская Е.В. Сегрегационный и генетико-дисперсионный анализ родословных больных раком молочной железы Киевского района // Цитол. и генетика.-1995.-Т.25.-с.48.

7. Бермишева М.А., Зинаеуллина Г.Ф., Ганцев Ш.Х. и соавт. Частота выявления мутации 5382insC гена BRCA1 у больных раком молочной железы // Вопр. онкол.-2008.-Т.54.-с.31.

8. Берштейн JI. М. Онкоэндокринология // СПб. Наука. 2004.-c.343.

9. Бородай Н.В. Роль генетических компонентов в возникновении и развитии опухолей // Злокачественные новообразования. Материалы научно практ. конф. «Взаимодействие аспектов комплексного лечения рака молочной железы.-2002.-К.-с.21-25.

10. Бородай Н.В. Клинико-генетическое обследование больных раком молочной железы // Онкология.-1999.-Т.4.-С.290-293.

11. Горбунова И.Н., Баранов B.C. Введение в молекулярную диагностику и генотерапию наследственных заболеваний // СПб: Специальная литература.-1997.

12. Бохман Я.В. Руководство по онкогинекологии //JI.,1989.-464c.

13. Буланов М.Н. Ультразвуковая диагностика в гинекологической практике // М.-2002.

14. Верморкер Я. Эпителиальный рак яичников: состояние проблемы // Материалы Второй ежегодной российской онкологической конференции.-М.-1999.-с.85-88.

15. Винокуров В.Л. Рак яичников: Закономерности метастазирования и выбор адекватного лечения больных // Монография.-2004.-М.-336с.

16. Ганина К. Роль генетического компонента в онкологии // Цитология и генетика.-1993.-Т.27-№4.-с.96-104.

17. Гилязетдинова З.Ш., Михайлов М.К. Онкогинекология: Руководство для врачей //М.МЕД-пресс-информ.-2002.-383с.

18. Грудинина H.A., Голубков В.И., Тихомирова О.С. и соавт. Идентификация мутаций в гене BRCA1 у больных раком молочной железы Санкт-Петербурга // Вестник РНЦРР МЗ РФ.-2006.-№3.-с.22-29.

19. Ганина К. Роль генетического компонента в онкологии // Цитология и генетика.-1993.-Т.27-№4.-с.96-104.

20. Гилязетдинова З.Ш., Михайлов М.К. Онкогинекология: Руководство для врачей //М.МЕД-пресс-информ.-2002.-383с.

21. Грудинина H.A., Голубков В.И., Тихомирова О.С. и соавт. Идентификация мутаций в гене BRCA1 у больных раком молочной железы Санкт-Петербурга // Вестник РНЦРР МЗ РФ.-2006.-№3.-с.22-29.

22. Давыдов М.И. Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2002г. // ГУ РОНЦ им. Н.Н.Блохина РАМН. -М.МИА.-2004.-с.256.

23. Давыдов М.И. Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. // Вестник Российского научного центра им.Н.Н. БлохинаРАМН.-2006.-М.-132с.

24. Жорданиа К.И., Козаченко В.П. и соавт. Клинические особенности семейного рака органов женской репродуктивной системы // Материалы 5-го Всероссийского съезда онкологов.-Казань.-2000г.-Т.2• с.440-442.

25. Жорданиа К.И. Некоторые аспекты диагностики и лечения рака яичников // Русский мед. журнал 2002.-№24.-с.1095-1102.

26. Жорданиа К.И. Оптимизация диагностики и лечения рака яичников // Автореф. дис. д-ра мед. наук. М.,1992.

27. Заридзе Д.Г., Мень Т.Х. Приоритетные направления противораковой • борьбы в России // Рос.онкол.журн.-2001.№5.-с.5-15.

28. Иванова О.С., Сельчук В.Ю., Иванова Л.Ф. и соавт. Сравнительный анализ морфологических особенностей BRCAl-ассоциированного ракамолочной железы // Вестник РОНЦ им.Н.Н.Блохина.-2007.-Т.18.-№4.-с.50-53.

29. Иванова О.С., Чистякова С.С., Гребенникова О.П., Сельчук В.Ю. Сравнительная характеристика клинических особенностей РМЖ в зависимости от патологического BRCA-генотипа // Клиническая онкология.-2006.-М.-с.29.

30. Имянитов E.H., Калиновский В.П., Князев П.Г. и соавт. Молекулярная генетика опухолей человека // Вопр. онкол.-1998.- Т.13.-№1.-с.95-101.

31. Имянитов E.H., Хансон К.П. Молекулярные аспекты патогенеза первично-множественных опухолей // Росс.онкол.журн.-1998.-№5.-с.47-51.

32. Имянитов E.H. Молекулярный патогенез рака молочной железы // Восьмой Российский онкологический конгресс.-2004.-с.22-23.

33. Имянитов E.H. Геронтологические аспекты молекулярной онкологии // «Успехи геронтологии».-1999.- №3.

34. Карпухин A.B., Логинова А.Н., Хомич Е.А., Поспехова Н.И. Наследственная предрасположенность к раку молочной железы // Мед. генет.-2002.-Т. 1 .-№6.-с.254-261.

35. Карпухин A.B., Поспехова Н.И., Любченко Л.И. и соавт. Частоты олигонуклеотидных полиморфизмов и мутаций в гене BRCA1 при наследственно обусловленном раке молочной железы и яичников // Доклады Академии наук.-2002.-Т.384.№12.-с.706-709.

36. Карпухин A.B., Поспехова Н.И., Музаффарова Т.А., Захаров С.Ф. и соавт. Молекулярная диагностика моногенных форм рака // Медицинская генетика. 2006.- Т.5.- Прилож.№2.- с.2-7.

37. Карселадзе А.И. Некоторые проблемы клинической морфологии эпителиальных опухолей яичников // Практ. онкол.-2000.-Т.4.-с.14-18.

38. Карселадзе А.И. Морфология эпителиальных опухолей яичников

39. Дисс. д-р мед. наук. М.-1990.

40. Кузнецов В.В., Блюмберг Г.Г., Лазарева И.Ю. и соавт. Опухоли яичников // Профилактика, ранняя диагностика и лечение злокачественных новообразований.-2005.-с.287-299.

41. Колосов А.Е. Опухоли яичников и прогноз для больных // Киров.-1996.-208с.

42. Логинова А.Н., Поспехова Н.И., Любченко Л.Н. и соавт. Спектр мутаций в гене BRCAlnpn наследственных формах рака молочной железы и яичников в российских семьях // Бюл.эксперим.биол.мед.-2003.-Т.136.-С.315-317.

43. Любченко Л.Н., Портной С.М., Брюзгин В.В. и соавт. Молекулярная медицина // М.-2007.

44. Маккэй Д. Клиническое применение последних открытий в генетике рака // Материалы Второй ежегодной российской онкологической конференции. M.-1999.-C.39-42.

45. Мандельштам М.Ю., Голубков В.И., Ламбер Е.П. и соавт. Поиск часто встречающихся мутаций в генах предрасположенности к раку молочной железы // Генетика.-2001.-Т.31.№12.-с.1681-1686.

46. Мерабишвили В.М., Попова С.П., Урманчеева А.Ф. и соавт. Анализ онкогинекологической заболеваемости и оценка эффективности лечения злокачественных опухолей женских гениталий в Санкт-Петербурге // Вопр.онкол.-1999.-№3.-с.233-238.

47. Мерабишвили В.М. Статистическая оценка возникновения риска злокачественных новообразований и анализ онкоситуации на популяционном уровне // Вопр. онкол.- 2008.-Т.54.-№2.-с.148-156.

48. Мерабишвили В.М. Выживаемость онкологических больных // СПб.-2006.

49. Нечаева И.Д. Опухоли яичников // Л.,Медицина.-1987.-208с.

50. Новикова Е.Г., Роиииа Е.А. Особенности эпидемиологии и современные методы диагностики злокачественных опухолей яичников // Гинекология.-1999.-№2.-с.42-44.

51. Новикова Е.Г., Ронина Е.А. Некоторые эпидемиологические показатели и диагностика злокачественных опухолей яичников // Материалы пленума проблемной комиссии: «Диагностика и лечение гинекологических заболеваний».-1998.-С.11-117.

52. Паличенко И.В. Факторы прогноза у больных раком яичников // Диссерт. канд. мед. наук.-1998.

53. Османова Л.И. Цели и задачи адъювантной и неадъювантной терапии рака молочной железы // Пятая Российская онкологическая конференция.-2001 .-с.ЗЗ.

54. Полищук JI.3., Несина Н.П., Новак Е.Е. Рак яичника: генетические изменения и их связь с клиническими особенностями опухолевого процесса // Онкология.-2002.-Т.4.-№1.-с.9-14.

55. Полищук JI.3. Наследственный рак, онкогенетические синдромы и • принципы генетической профилактики злокачественныхновообразований // Doctor.-2003.-T.4.-c.46-49.

56. Поспехова H.H., Логинова А.Н., Любченко Л.Н., Гарькавцева Р.Ф. и соавт. Гетерогенность семей с наследственной предрасположенностью к раку молочной железы и яичников по встречаемости мутаций в гене BRCA1 //Мед. генет.-2003.-Т.2№11.-с.459-463.

57. Поспехова Н.И., Логинова А.Н, Смирнова Т.Ю. и соавт. Исследование взаимосвязи генотипа и фенотипа при мутациях в гене BRCA1 // Медицинская генетика.- 2005.-Т.4.- № 6.- с. 254.

58. Сельчук В.Ю., Попова Т.Н., Аверьянова C.B. Первично-множественные синхронные злокачественные новообразования репродуктивной системы у женщин // Российский онкологический журнал.-2001 .-Т.З.-с. 18-21.

59. Смирнова Т. Ю., Карпухин A.B. Наследственная предрасположенность к раку яичников // Медицинская генетика.- 2007.- Т.6.- № 5.-С.9-13.

60. Тюляндин С.А. С.А. Рак яичников // М.-1996.-63с.

61. Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников // Практ. онкол.-2000.-Т.4-с.7-13.

62. Урманчеева А.Ф. Региональная программа лечения больных раком яичника 3-4 стадии // 7 Российский онкологический конгресс. «Современные возможности лекарственной терапии».-2003.

63. Урманчеева А.Ф., Мешкова И.Е. Практическая онкология // 2000.-№4.-с.7-13.

64. Урманчеева А.Ф., Бурнина М.М. Заместительная гормонотерапия и злокачественные опухоли // Журнал акушерских и женских болезней2000.-№1.-с.58-62.

65. Хансон К.П., Имянитов Е.Н. Молекулярная генетика рака яичников // Практ. онкол.-2000.-Т.4.-с.З-6.

66. Чиссов В.И., Старинский В.В. Злокачественные новообразования в России в 2000 году (заболеваемость и смертность) М.: МНИОИ им. П.А.Герцена. - 2002.-264С.

67. Чиссов В.И., Трахтенберг А.Х. Первично-множественные злокачественные опухоли // Руководство для врачей.- М. Медицина.-2000.-336с.

68. Чиссов В.И. Клинические рекомендации // Раздел онкология.-2007.-720с.

69. Чимитдаржиева Т.Н. Особенности клинического течения «семейного рака яичников» // Диссертация канд. мед. наук. М.-1998.

70. Abeliovich D., Hubert A., Sagi M., et al. Clinical and histological characteristics of breast and ovarian cancer patients carrying the BRCA1/2 mutations // Paris, France.-1997.

71. Allinen M., Huusko P., Launonen V., et al. Mutation analysis of the CHEK2 gene in families with hereditary breast cancer // BrJ.Cancer.-2001.-V.85.-P.209-212.

72. Allione F., Eisinger F., Pare P., et al. Loss of heterozygosity at loci from chromosome arm 22q in human sporadic breast carcinomas // Int. J. Cancer. -1998.-V.75.-P. 181-186.

73. Anandakurmar C., Chew S., Wong Y., et al. Role of transvaginal ultrasound color flow imaging and malignant ovarian tumors // Ultrasound Obstet. Gynecol. Oncol.-1996.-V.7.-c.280-284.

74. Anglian Breast Cancer Study Group // Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases // Br. J. Cancer.- 2000.-V.83.-P.1031-1038.

75. Antoni L., Sodha N., Collins I., et al. Chk2 kinase cancer susceptibility and cancer therapy -two sides of the same coin // Nat.Rev.Cancer.-2007.-V.7.-P.925-936.

76. Antoniou A., Gayther S.A., Stratton J.F., et al. Risk models for familial ovarian and breast cancer // Genet. Epidemiol.-2000.-V-P.76-83.

77. Antoniou A., Easton D.F. Models of genetic susceptibility to breast cancer // C)ncogene.-2006.-V.25.-P.5898-5905.

78. Antoniou A., Pharoah P.D., Narod S., et al. Breast and ovarian cancer risk to carriers of the BRCA1 5382inc C and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies // J.Med.Genet.-2005.-V.42.-P.602-603.

79. Antoniou A., Pharoah P.D., McMullan G., et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes // Br.J.Cancer.-2002.-V.86.-P.76-83.

80. Armes J., Egan A. Southy M., et al. The histologic phenotypes of breast carcinoma occurring befor 40 years in women with and without BRCAlor BRCA2 germline mutations // Cancer.-1998.-V.83.-P.2335-2345.

81. Beckmann M.W., Picard F., An Hx., et al. Clinical impact of detection of loss heterozygosity of BRCA1 and BRCA2 markers sporadic breast cancer //Br. J. Cancer.-1996.-V.73.-P. 1220-1226.

82. Baldwin R.L., Nemeth E., Tran H., et al. BRCA1 promoter region Hypermethylation in ovarian carcinoma: a population-based study // Cancer Res.-2000.-V.60.-P.5329-5333.

83. Bandera C.A., Muto M.G., Schorge J.O., et al. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum // Obset. Gynecol.-1998.-V.92.-P.596-600.

84. Ben David Y., Chérit A., Hirsch-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors // J. Clin. Oncol.-2002.-V.20.-P.463-466.

85. Bartek J., Falck J., Lukas J., CHEK2 kinase: a busy messanger // Nat.Rev.Mol.Cell.Biol.-2001.-V.2-P.877-886.

86. Bartek J., Lukas J. Chkl and Chk2 kinases in checkpoint control and cancer // Cancer cell.-2003.-V.3-P.421-429.

87. Bartkova J., Horejsi Z., Koed K., et al. DNA damadge response as a candidate anti-cancer barrier in early human tumorogenesis // Nature.-2005.-V.434.-P.864-86-70.

88. Bay sal B.E., De Loia J.A., Willet-Brozick J.E., et al. Analysis of CHEK2 gene for ovarian cancer susceptibility // Gynecol.Oncol.-2004.-V.95.-P.62-69.

89. Bell D.W., Varley J.M., Szydlo T.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome // Science.-1999.-V.286.-P.2528-2531.

90. Bernstein J.L., Thompson W.D., Risch N., et al. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a primary breast cancer// Am J. Epidemiol.-1992.-V.136.-P.925-936.

91. Bernstein J. L., Henderson B.E., Hanisch R., et al. Physical exercise and reduced risk of breast cancer in young women // J. Natl. Cancer Inst.-1994.-V.86.-P. 1403-1408.

92. Bernstein J. L., Douglas T., et al. Comparison of Techniques for the Successful detection of BRCA1 mutations in fixed paraffin-embedded tissue // Cancer. Epidemiol. Biomark. -2002. V.11.-P.809-814.

93. Bertone-Johnson E. Epidemiology of ovarian cancer: a status report // Lancet.-2005.-V.365.-P. 101-102.

94. Bianco T., Chenevix-Trench G., Walsh D., et al. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer // Carcinogenesis.-2000.-V.21.-P. 147-151.

95. Breeks A., de Witte L., Noojen A., et al. Excess risk for contrlateral breast cancer in CHEK2*1100delC germline mutation carriers // Breast Cancer Res.-2004.-V.83.-P.91-93.

96. Berek Y., Martinez-Maza O. Molecular and biological factors in the pathogenesis of ovarian cancer // J. Ovarian cancer. 1995.-V.3-P.77-78.

97. Berek Y. Germ cell tumors of the ovary. Post graduate our se: Gynecologic oncology. Presented at the annual meeting of the American College of obstetricians and Gynecologists // Las Vegas.-1987.

98. Berek Y. Intraperitoneal therapy in ovarian cancer // International society of Gynecologic Oncology.-1987.-Amsterdam.

99. Berrino F., Cascinell N. Cancer prevalence. What for? // Tumori.-1999.-V.85 (5).-P.414-417.

100. Bewtra C., Watson P., Conway T.et al. Hereditary ovarian cancer: a clinicopathological study// Int.J. Gynecol. Patol. -1992. -V.ll. -P.180-187.

101. Bignon Y., Fonck Y., et al. Histoprognostic grade in tumors from families with hereditary predisposition to breast cancer // Lancet.-1995.-V.346.-P.258.

102. BogdanovaN., Enssen-Dubrowinskaya N., Feshchenko S., et al. Association of two mutations in the CHEK2 gene with breast cancer // Int .J.Cancer.-2005.-V.116.-P.263-266.

103. Borg A. Molecular and pathological haracterization of inherited breast cancer// Cancer Biol.-2001.-V.ll.-P.375-385.

104. Botha J.L., Bray F., Sankila R., Parkin D.M. Breast cancer incidence and mortality trends in 16 European countries // Eur. J. Cancer.-2003.-V.39.-P.1718-1729.

105. Boune T.H. Can ovarian masses be characterized using ultrasound // Editorial. Gynecol. Oncol.-1993.-V.51.-P.4-6.

106. Boune T.H., Campbell S., Collins W.P. Screening for ovarian cancer // Brit. Medical. J. -1993.-V.306.-P.1685.

107. Boune T.H., Campbell S., Reynolds K., et al. The potential roll of Serum Ca 125 in an ultrasound-based Screening program for familial ovarian cancer // Gynecol. Oncol.-1994.-V.52.-P.379-385.

108. Boyd M., Rubin S. Hereditary ovarian cancer: molecular genetics and clinical implications //Gynecol. Oncol.-1997.-V.64.-P. 196-206.

109. Boyd M., Harris F., et al. A human BRCA1 gene knockout // Nature.-1995.-V.375.-P.541-545.

110. Boyle P., Ferlay J. Cancer incidence and mortality in Europe // Ann.Oncol.-2005.-V.16.-P.481-488.

111. Boyd M. Specific keynote: Hereditary Ovarian cancer: what we know //Gynecol. Oncol.-2003.-V.88.-P.8-10.

112. Breast Cancer Linkage Consortium. Carrier risks in BRCA2 mutation carries //J. Natl. Cancer. Inst. 1999. -V.91. -P.1310-1316.

113. Breast Cancer Information Core (BIC) // research, nhgri.nih.gov/bic.

114. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., et al. Survival and prognostic factors in BRCA 1-associated breast cancer //Ann.0ncol.-2006.-V.17.-P.391-400.

115. Brekelmans C.T., Seynaeve C., Bartels C.C., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk // J. Clin. Oncol.- 2001.-V.19.-P.924-930.

116. Brinton L.A., Daling J.R., Liff J.B., et al. Oral contraceptives and breast cancer risk among younger women // J. Natl. Cancer Inst.-1995.-V.87.-P.827-835.

117. Brody L.C., Tucker M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews // N.Engl.J.Med.-1997.-V.336.-P. 1401-1408.

118. Broeks A., de Witte L., Nooijen A., et al. Excess risk for contrlateral breast cancer in CHEK2 *1100delC germline mutation carriers // Breast Cancer.Res.Treat.-2004.-V.83.-P.91-93.

119. Brunet J.S., Narod S.A., Tonin P., et al., BRCA1 mutations and survival in women with ovarian cancer // N. Engl. J. Med.-1997. V.336.-P.1256.

120. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program // J. Natl. Cancer Inst.- 2002.-V.94.-P. 1365-1372.

121. Brouillet J.P., Dujardin M.A., Chalbos D., et al. Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer // Int.J.Cancer.-2001.-V.95.P.205-208.

122. Bjurne T.H., Campbell S., Reynolds K., et al. The potential role of serum Cal25 in an ultrasound-based screening programm for familial ovarian cancer // Gynecol.Oncol.-1994., Mar.-1994.-V.52.-P.379.

123. Caligo M.A., Agata S., Aceto G., et al. The CHEK2*1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy // Hum. Mutat.-2004.-V.24.-P. 100-1001.

124. Campbell S., Bhan V., Royston P., Whitehead M.I., et al. ultrasound screening for early ovarian cancer// Br. Med. J.-1989.-V.299.-P.1363.

125. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma // Cancer.-2003.-V.97.-P.2187-2195.

126. Carlson K.J., Skates S J., Singer D.E. Screening for ovarian cancer // Ann.Intern.Med.-1994.-V.121.-P.124.

127. Cybulski C., Gorski B., Huzarski T., et al. CHEK2 is a multiorgan cancer susceptibility gene//J. Hum. Genet.-2004. -V.111.-P.1131-1135.

128. Chappuis P.O., Nethercot V., Foulkes W.D. Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer // Semin.Surg.Oncol.-2000.-V. 18 .-P.287-295.

129. Chapman M.S., Verma I.M. Transcriptional activation by BRCA1 // Nature.-1996.-V.382.-P.678-679.

130. Chaturvedi P., Eng W.K., Zhu Y., et al. Mammalian CHEK2 is a downstream effect or of the ATM-dependent DNA damage checkpoint pathway // Oncogene.- 1999.-V.18.-P.4047-4054.

131. CHEK2 Breast Cancer Consortium Low-penetrance susceptibility to breast cancer due to CHEK2 -11 OOdelC in noncarriers of BRCA1 or BRCA2 mutations // Nat.Genet.-2002.-V.31.-P.55-59.

132. CHEK2 Breast Cancer Case-Control Consortium: CHEK2 *1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies // Am J.Hum.Genet.-2004.-V.74.-P.1175-1182.

133. Chekmariova E.V., Sokolenko A.P., Buslov K.G., et al. CHEK2* 11 OOdelC mutation is frequent amoug Russian breast cancer patients // Breast Cancer Res.Treat.-2006.-V.100.-P.99-102.

134. Claus E.B., Schildkraut J., Thovpson W., et al. The genetic attributable risk of breast and ovarian cancer // Cancer.-1996.-V.77.-P.2318-2324.

135. Claus E.B., Risch N., Thompson W.D. Genetic analysis of breast cancer in the cancer and steroid hormone study // Am. J. Hum. Genet. 1991. -V.48.-P.232-242.

136. Chen Q., Neuhausen S., Shattuck-Eidens D., Godwin A., et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families // Nature.Genet.-1996.-V. 13.- P. 123-125.

137. Chen Y., Chen C., Riley D., et al. Aberrant subcellular localization of BRCA1 in breast cancer // Science.-1995.-V.270.-P.789-791.

138. Chen J., Hedman M.Z., Arver B., et al. BRCA2 germline mutations in Swedish breast cancer families // Eur.J.Hum.Genet.-1998.-V.6.-P.134-139.

139. Chenevix-Trench G., Spurdle A.B., Gatei M., et al. Dominant negative ATM mutations in breast cancer families // J.Natl.Cancer.Inst.-2002.-V.94.-P.205-215.

140. Ciernikova S., Tomka M., Kovac M., et al. Ashkenazi founder BRCA1/ BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families // Neoplasma.-V.53.-P.97-102.

141. Cordon-Cardo C. Mutation of cell gene regulators. Biological and clinical implications for human neoplasia// Am.J.Pathol.-1995.-V.47.-P.531-540.

142. Cornells R.S., Neuhausen S.L., Johansson O., et al. High allele loss rates at 17ql2-q21 in breast and ovarian tumors from BRCAl-linced families // The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer.-1995.-V.13.-P.203-210.

143. Coleman M.P., Hermon C., Douglas A. Person-years (PYRS) -a for trans program for cohort study analysis // Lyon: IARC internal report.-1989.

144. Concannon P. ATM heterozygosity and cancer risk // Nat.Genet.-2002.-V.32.-P.89-90.

145. Couch F.J., Weber B.L. Breast cancer // The genetic basis of human cancer.1998.-M.Graw-Hill, New York -P.537-563.

146. Couch F.J., Deshano M.L., Blackwood M.A., et al., BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer // N.Engl.J.Med.-1997.-V.336.-P. 1409-1415.

147. Colditz G.A., Rosner B., Chen W.Y., et al. Risk factors for breast cancer according to estrogen and progesterone receptor status // J. Nat. Cancer Inst.-2004.-V.96.-P.218-228.

148. Craig A.L., Hupp T.R. The regulation of Chk2 in human cancer // Oncogene.-2004.-V.4.-P.8411.

149. Csokay B., Tihomirova L., Stengrevics A., et al. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia // Hum.Mutat.1999.-V.14.-P.92.

150. Cybulski C., Gorski B., Huzarski T., et al. CHEK2 is a multiorgan cancer susceptibility gene // Am J. Hum. Genet.-2004.-V.75.-1131-1135.

151. Cybulski C., Gorski B., Huzarski T., et al. CHEK2-positive breast cancer in young Polish women // Clin. Cancer. Res.-2006.-V.12.-P.4832-4835.

152. Dach G.U., Dougherty G.J., Stratford I.J., Chaplin D.J., et al. Early detection of familial ovarian cancer // Eur.J.Cancer.-1996.-V.32.-№10.-P.1645-1651.

153. Dach G.U., Dougherty G.J., Stratford L.J., et al. Targeting gene therapy to cancer: a review // Oncol.Res.-1997.V.9.-P.313.

154. Diez O., Osorio A., Duran M., et al. Analysis of BRCA! And BRCA2 genes in Spanish breast/ovarian cancer patients a high proportion of mutations unique to Spain and evidence of founder effects // Hum. Mut. -2003. -V.22.-P.301-312.

155. Dobrovic A., Simpfendorfter D. Methylation of the BRCA1 gene in sporadic breast cancer //. Cancer Res.-1997.-V.57.-P.3347-3350.

156. Dong X., Wang L., Taniquchi K., et al. Mutations in CHEK2 associated with prostate cancer risk // Am J.Hum.Genet.-2003.-V.72.-P.270-280.

157. Dorum A., Kristensen G.B., Abeler V.M., et al. Early detection of familial ovarian cancer // Eur.J.Cancer.-1996.-V.10.-P.1645.

158. Dowsett M. Improved prognosis for biomarkers in breast cancer // Lancet.1998.-V.351.-P.1753-1754.

159. Dubeau L. Ovarian cancer // The genetic basis of human cancer.-1998. -M.Graw-Hill, New York -P.615-620.

160. Dufault M.R., Betz B., Wappenschmidt B., et al. Limited relevance of the CHEK2 gene in hereditary breast cancer // Int. J. Cancer.-2004.-V.110.-P.320-325.

161. Dunning A.M., Healey C.S., Pharoah P.D., et al. A systematic review of genetic polymorphisms and breast cancer risk // Cancer Epidemiol.Biomark.Prev.-1999.-Y.-P.843-854.

162. Dupont W.D., Page D.L. Risk factors for breast cancer in women proliferative breast diseas // N. Engl. J. Med.-1985.-V.312.-P. 146-151.

163. Dunning A.M., Chiano M., Smith N.R., et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population // Hum. Mol. Genet.-1997.-V.6.-P.285-289.

164. Easton D.F., Ford D., Bishop D.T., et al. Breast and ovarian cancer incidence in BRCA1- mutation carriers // Am J. Hum. Genet. -1995. -V.56.-P.265-271.

165. Easton D., Clayton D., Ponder B.A., Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population // Hum.Mol.Genet.-1997.-V.6.-P.285-289.

166. Easton D. F. Breast cancer gene what are the real risk? // Nature Genet.-1997.-V.16.-P.210-211.

167. Easton D.F., Bishop D.T., Ford D., et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families // Am J. Hum. Genet.1999. V.52.-P.678-701.

168. Eerola H., Heikkial P., Tomminen A., Aittomaki K., et al. Relationship of patients age to histopathological features of breast tumors in BRCA1 and BRCA2 and mutation-negative breast cancer families // Breast Cancer Res.-2005.-V.7.-P.465-469.

169. Einhorn N., Syovall K., Knapp R.C., et al. Prospective evaluation of serum Ca-125 levels for early detection of ovarian cancer // Obstet. Gynecol.-1992.-V.80.-P. 14.

170. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study//J. Clin.0ncol.-2005.-V.23.-P.7491-7496.

171. Eisinger F., Jacquemier J., Guinebretier J., et al. P53 involvement in BRCA-associated breast cancer// Lancet.-1998.-V.351.-P.1633-1634.

172. Eisinger F., Stoppa-Lyonnet D., Longy M., et al. Germ line mutation at BRCA1 affects the histoprognostic grade hereditary breast cancer // Cancer.-1996.-V.56.-P.471-474.

173. Eisinger F., Alby N., Bremond A., et al. Recommendations for medical management of hereditary breast and ovarian cancer the French National Ad Hoc Committee //Ann. Oncol.-998.-V.9.-P.939.

174. Elledge S. Cell cycle checkpoints: preventing an identity crisis // Sciens.1996.-V.274.-P. 1664-1672.

175. Ewertz M., Duffy S.W., Adami H.O., et al. Age at parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries // Int. J. Cancer.-1990.-V.46.-P.597-603.

176. Falck J., Mailand N., Sylijuasen R.G., Bartek J., et al. The ATM-Chk2-25A checkpoint pathway guards against radioresistant DNA synthesis // Nature.-2001.-V.410.-P.842-847.

177. Fedorova O.E., Liubchenko L.N., Paiadini I., et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries patients of Russian population using biochips // Mol.Biol.(Mosk.).- 2007.-V.41. -P.37-42.

178. Feunteun J., Narod S.A., Lynch H.T., et al. A breast-ovarian cancer susceptibility gene maps to chromosome 17q21 // Am J.Hum.Genet.-1993.-V.52.-P.736-742.

179. FitzGerald M.G., Bean J.M., Hegde S. R., et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer // Nat.Genet.1997.-V.15.-P.307-310.

180. Ford D., Easton D.F., Stratton M., Narod S.A., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families // Am J.Hum.Genet.-1998.-V.62.-P.676-689.

181. Ford D., Easton D.F., Bishop D.T., Narod S.A., et al. Consortium BCL. Risks of cancer in BRCA1-mutation carriers // Lancet.-1994.-V.343.-P.692-695.

182. Ford D., Easton D.F., Bishop D.T. Breast and ovarian cancer incidence in BRCA1 mutation carriers // Am.J.Hum.Genet.-1995.-V.56.-P.265-271.

183. Ford D., Easton D.F., Bishop D.T., et al. Consortium BCL. Risk of cancer in BRCA1-mutation carriers // Lancet.-1994.-V.343.-P.692-695.

184. Fodor F.H., Weston A., Bleiweiss I.J. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients // Am.J.Hum.Genet.-1998.-V.63.-P.45-51.

185. Foretova L., Machackova E., Navratilova M., et al. BRCA1 and BRCA2 mutations in women with familial or early-onset breast /ovarian cancer in the Czech Republic // Hum.Mutat.-2004.-V.23.-P.397-398.

186. Foulkes W.D., Wong N., Rozen E., et al. Survival of patients with breast cancer andBRCAl mutations //Lancet.-1998.-V.351.-P.1351.

187. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk//J. Clin. Oncol.- 1998.-V. 16.-P.2417-2425.

188. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals//J. Clin. Oncol.-2002.-V.20.-P. 1480-1490.

189. Frank T.S., Critcfie G.C., et al. Hereditary risk of Women is cancers // Best. Pract. Res. Obstet. Gynecol.-2002.-V.16 (15).-P.703-713.

190. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk//J. Clin. Oncol.-1998.-V.16- P.2417-2425.

191. Friedman L.S., Ostermeyer E.A., Szabo C., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families //Nature Genet.-1994.-V.8.-P.399-404.

192. Friedman L.S., Ostermeyer E.A., Szabo C.I., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in families // Nature Grnet.-1994.-V.8.-P.399-404.

193. Friedman L.S., Gayther S.A., Kurosaki T., et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population // Am J. Hum. Genet.-1997.-V.60.-P.313-319.

194. Friedrichsen D.M., Malone K.E., Doody D.R., et al. Frequency of CHEK2 mutations in population based case-control study of breast cancer in young women // Breast Cancer Res.-2004.-P.6.-P.629-635.

195. Futreal P.A., Liu Q., Shattuk-Eidens D., Cochran C., et al. BRCA1 mutations in primary breast and ovarian carcinomas // Science.-1994.-V.266.-P. 120-122.

196. Gad S., Caux-Moncoutier V., Pages-Berhouet S., et al. Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families // Oncogene.-2002.-V.21.-P.6841-6847.

197. Gallion H.H., Guarino A., DePriest P.D., et al. Evidence of unifocal origin in familial ovarian cancer // Am J. Obstet Gynecol.-1996.-V. 174.-P.1102-1106.

198. Gayther S.A., Warren W., Mazoyer S., Russel P.A., et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype correlation // Nature Genet.-1995.-V.ll.-P.428-433.

199. Gayther S.A. Frequently occring germ line mutations of BRCA1 gene //Am .J.Hum.Genet.-1997.-V.60.-FA 013-1020.

200. Gayther S.A., Harrington P., Russell P., et al. Frequently occurring germline mutations of the BRCA1 gene in ovarian cancer families from Russia // Am. J.Hum.Genet.-1997.-V.60.-P. 1239-1242.

201. Gayther S.A., Harrington P., Russell P., et al. Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis // Am.J.Hum.Genet.-1996.-V.60.-№5 .-P. 1239-1242.

202. Gayther S.A., Mangion J., Russel P., et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of BRCA2 gene //Nat. Genet.-1997.-V.15.-P. 103-105.

203. Gauderman W.J. Sample size requirements for matched case-control studies of gene-environment interaction // Stat.Med.-2002.-V.21.-P.35-50.

204. Ghimenti C., Sensi E., Presciuttini S., et al. Germline mutations of the BRCAl-associated ring domain gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations // Gene Chromosome Canc.-2002.-V.33.-P.235-242.

205. Girzybowska E., Zientek H., Jesinska A., et al. High frequency of recurrent mutations in the BRCA1 and BRCA2 in Polish families with breast and ovarian cancer // Hum.mutat.-2000.-V.16.-P.482-490.

206. GLOBOCAN // www. dep. iarc. fr. -2000.

207. Godard B., Foulkes W.D., Provencher D., et al. Risk factor for familial and sporadic ovarian cancer among French Canadians: a case-control study // Am J. Obstet. Gynecol.-1998.-V.179.-P.403-410.

208. Gorski B., Byrski T., Huzarski T., et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer // Am. J.Hum.Genet.-2000.-V.66.-P. 1963-1968.

209. Gorski B., Jakubowska A., Huzarski T., Birski T., et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families // Int. J. Cancer.-2004.-V.110.-P.683-686.

210. Grabrick D.M., Hartmann L.C., Cerhan J.R., et al. Risk of breast cancer with oral contraceptive use women with a family history of breast cancer // JAVA.-2000.-V. 11 .-P.284-2814.

211. Greene M.H., Dark J.W., Blayney D.W. The epidemiology of ovarian cancer // Semin. Oncol. 1984.- V.11.-P.209.

212. Greene M.H.: Genetics of breast cancer // Mayo Clin.Proc.-1997.-V.72.-P.54-65.

213. Gross T.P., Schlesselman J.J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer // Obstet.Gyntcol.-1994.-V.83.-P.419.

214. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes // Nature.-2007.-V.446.-P.153-158.

215. Gronwald J., Jauch A., Cybulski C., et al. Comparison of genomic abnormalities between BRCA and sporadic breast cancer studied by comparative genomic hybridization // Int. J. Cancer.-2005.-V.114.-P.230-236.

216. Gruvberger S., Ringner M., Chen Y., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns // Cancer Res.-2001.-V.61.-P.5979-5984.

217. Grzybowska E., Zientek H., Jasinska A., Rusin M., et al. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer // Human Mutat.-2000.-V.16.-P.482-490.

218. Hakansson S., Johannsson O., Johannsson U., et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer // Am J. Hum. Genet.-1997.-V.60.-P.1068-1078.

219. Hall J.M., Newman B., Morrow J.E., et al. Linkage of early-onset familial breast cancer to chromosome 17q21 // Science.-1990.-V.250.-P.1684-1690.

220. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers // J. Natl. Cancer Inst.-2001.-V.93.-P. 1633-1637.

221. Hartwell L.H. Defects in a cell cycle checkpoin may be responsible for the genomic instability of cancer cells.- 1992.-V.71.-P.543-546.

222. Hartwell L.H., Kastan . Cell cycle control and cancer // Science.-1994.-V.266.-P.1821-1828.

223. Hisada M., Garber J.E., et al. Multiple primary cancers in families with Li-Fraumeni syndrome//J. Nat. Cancer. Inst.-1998.-V.90. -P.606-611.

224. Hankinson S.E., Colditz G.A., Hunter D.A., et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer // Obstet. Gynecol.-1993.-V.270.-P.708-714.

225. Hankinson S.E., Hunter D.J., Colditz G.A., et.al. Tubal ligation hysterectomy and risk of ovarian cancer // A prospective study.JAMA.-1993.-V.270.-P. 2813-2818.

226. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer// N. Engl. J. Med.- 2001.-V.344.-P.539-548.

227. Hilton J.L., Geisler J.P., Rathe J.A., et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer// J. Natl. CancerInst.-2002.-V.94.-P.1396-1406.

228. Hirsh-Yechezkel G., Chetrit A., Lubin F., et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel // Gynecol.Oncol.-2003.-V.89.-P.494-498.

229. Hogervorst F.B., Comelis R.S., Bout M., et al. Rapid detection of BRCA1 mutations by the protein truncation test // Nat. Genet.-1995.-V.10.-P.208-212.

230. Holt J., Thompson M., Szabo C., et.al. Growth retardation and tumor inhibition by BRCA1 // Nature Genet.-1997.-V.12.-P.298-303.

231. Hosking L., Trowsdale J., Nicolai H., et al. A somatic BRCA1 mutation in an ovarian tumor//Natur.Genet.-1995.-V.9.-P.343-344.

232. Howlstan R.S., Bourne T., Collins W.P., et al. Risk of ovarian cancer and genetic relationship to other cancers in families // Hum. Heredit. -1993. -V.43.-P.11-115.

233. Heijboer E.J., Klijn J. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1 // Lancet.-1998.-V/351.-P.316-321.

234. Hulka B.S. Epidemiologic analysis of breast and gynecologic cancers // Prog.Clin.Biol. Res.-1997. V.396.-P.17 -29.

235. Hunter K., Welch D.R., Liu E.T. Genetic background is an important of metastatic potential // Nat.Genet.-2003.-V.34.-P.5973-5981.

236. Huang J., Domchek S.M., Brose M.S., et al. Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers // J.Med.Genet.-2004.-V.41.-P.120.

237. Jacobs I., Davies A.P., Bridges J., et al. Prevalence screening for ovarian cancer in postmenopausal women by Ca-125 measurement and ultrasonography // Br. Med.J.-1993.-V.306.-P.159.

238. Jacquemir J., Eisinger F., Birnbaum D., et al. Histoprognostic grade in BRCA1 associated breast cancer// Lancet.-1995.-V.345.-P.1503.

239. Jasin M. Homologous repair of DNA damage and tumorogenesis: the BRCA connection // Oncogene.-2002.-V.21.-P.8981-8993.

240. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCAl-linced, BRCA2-linced and sporadic ovarian cancer // J. Natl. Cancer Inst.-2002.-V.94.-P.990-1000.

241. Jensen R., Thompson M., et al. BRCA1 is increted and exhibit properties of a granin // Nat.Genet.-1996.-V.12.-P.303-308.

242. Jeffrey S.S., Lonning P.E., Hillner B.E. Genomics-based prognosis and therapeutic prediction in breast cancer // J.Natl.Compr.Canc.Netw.-2005.- V.3.-P.291-300.

243. Johnson N., Fletcher O., Naceur-Lombardelli C., et al. Interaction between CHEK2:|: 1 lOOdelC and other low-penetrance breast-cancer susceptibility genes //Lancet.-2005.-V.366.-P. 1308-1314.

244. Johannsson O., Idvall I., Anderson C., et al. Tumor biological features of BRCAl-inducted breast and ovarian cancer // Eur.J.Cancer.-1997.-V.33-P.362-371.

245. Johannsson O., Loman N., Borg A., et al. Pregnancy-associated cancer in BRCA1 and BRCA2 germline mutation carriers // Lancet.-1998.-V.352.-P.1359-1360.

246. Johannsson O., Ostermeyer E.A., Hakansson S., et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in Southern Sweden // Am J. Hum. Genet.-1996.-V.58.-P.441-450.

247. Johannsson O.T., Ranstam J., Borg A., et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden // J.Clin.Oncol.-1998.-V.16.-P.397-404.

248. Johannsson O., Loman N., Moller U., et al. Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germline mutation carriers // Eur.J.Cancer.-1999.-V.35.-P. 1248-1257.

249. Ingvarsson S., Sigbjornsdottir B.I., Huiping C., et al. Mutation analysis of the CHEK2 gene in breast carcinoma and other cancers // Breast Cancer Res.-2002.-V.4.-P.4.

250. Karlan B.Y., Piatt L.D. Ovarian cancer screening. The role of ultrasound in early detection // Cancer.-1995.-V.15.-P.76.

251. Kasprzak L., Foulkes W.D., Shelling A.N. Hereditary ovarian carcinoma // Clinical review.BMG.-1999.-V.318.-P.786-789.

252. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutations // N.Engl.J.Med.-2002.-V.346.-P. 1609-1615.

253. Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer // Epidemiol. Rev.-1993.-V.15.-P.36-47.

254. Kerlikowski K., Brown J.S., Grady D.G. Should women with familial ovarian cancer undergo prophylactic oophorectomy // Obstet Gynecjl.-1992.-V.80.-P.700-707.

255. Key T.J. Studies in the epidemiology of sex hormones and cancer // Diss.Abstr.Int.-1991.-V.80.-P.3789.

256. Key T.J., Pike M.S. The role of oestrogens and progestagen. Epidemiology and prevention of breast cancer // Eur.J.Cancer Clin.Oncol.-1988.-V.24,-P.29-43.

257. Kilpivaara O., Bartkova J., Eerola H., et al. Correlation of CHEK2 protein expression and c/llOOdelC mutation status with tumor characteristics among unselected breast cancer patients // Int.J.Cancer.-2005.-V.113.-P.575-580.

258. KimM.A., KimH.J., Brown A.L., et al. Identification of novel substrates for human checkpointkinase chkl and chk2 through genome-wide screening using a consensus Chk phosphorylation motif // Exp.Mol.Med.-2007.-V.30.-P.205-212.

259. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA 2 // Science.-2003.-V.302.-P.643-646.

260. Kleibl Z., Novotny J., Bezdickova D., et al. The CHEK2*1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic //Breast Cancer Res.Treat.-2005.-V.90.-P.165-167.

261. Kristensen V.N., Borresen-Dale A.L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism // Mut. Res.-2000.-V.462.-P.323-333.

262. Krylova N.Y., Lobeiko O.S., Sokolenko A.P., et al. BRCA1 4153delA founder mutation in Russian ovarian cancer patients // Hered. Cancer in Clinic. Pract. -2006.-V.4.-P. 193-196.

263. Kuschel B., Auranen A., Gregory C.S. Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk // Cancer. Epidemiol. Biomarkers. Prev.-2003.-V.12.-P.809-812.

264. Kwiatkowska E., Teresiak M., Lamperska K.M., et al BRCA2 germline mutations in male breast cancer patients in the Polish population // Hum.Mutat.-2001.-V. 17 .-P.73.

265. Lahti-Domenici J., Rapakko K., et al. Exclusion of deletions and other rearrangements in BRCA1 and BRCA2 breast and ovarian cancer families // Cancer Genet. Cytogenet.-2001.-P.129.-P.120-123.

266. Laitman Y., Kaufman B., Lahad E.L., et al. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer // Isr.Med.Assoc.J.-2007.-V.9.-P.791-796.

267. Lakhani S.R., Jacquemier J., Sloane J.P., Gusterson B.A., et al. Multifactorial analysis of differences between sporadic breast cancers involving BRCA1 and BRCA2 mutations // J. Nat. Cancer Inst.-1998,-V.90.-P.1138-1145.

268. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype // Clin. Cancer Res.-2005.-V.ll.-P.5175-5180.

269. Lakhani S.R., Manek S., Penault-Llorca F., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers // Clin. Cancer Res.-2003.-V.2004.-P.2473-2481.

270. Lakhani S.R., Gusterson B.A., Jacquemier J., et al. The pathology of familial breast cancer histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2 // Clin. Cancer Res.-2000.-V.6.-P.782-789.

271. Lakhani S.R. The pathology of familial breast cancer: Morphological aspects // Breast Cancer Res.-1999.-V. 1 .-P.31-35.

272. Lalloo F., Varley J., Ellis D., et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history // Lancet.-2003.-V.361.-P.1101-1102.

273. Lancaster J.M., Wooster R., Mangion J., et al. BRCA2 mutations in primary breast and ovarian cancers // Nat. Genet.-1996.-V.13.-V.13.-P.238-240.

274. Langston A.A., Malone K.E., Thompson J.R., et al. BRCA1 mutations in a population-based sample of young women with breast cancer // N.Engl .J.Med.-1996.-V.334.-P. 137-142.

275. Lee J.S., Wacholder S., Struewing J.P. et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers // J. Nat. Cancer Inst.-199.-V.9l.-P.259-263.

276. Li F.P., Fraumeni J.F. Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome // Ann. Intern. Med. 1968.-V.71.- P.747-752.

277. Li J., Williams B., Haire L., et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2 // Mol.Cell.-2002.-V.9.-P. 1045-1054.

278. Lindblom A. Departments of Clinical Genetics and Oncology. Karolinska Hospinal, Stockholm, Karolinska Institute // A molecular study on familial breast cancer.-1993.

279. Litwiniuk M.M., Roznowski K., Filas U., et al. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers // BMC Cancer.-2008.-V.8.-P.100.

280. Liu H.X., Cartegni L., Zhang M.Q., et al. A mechanism for exon skipping causes by nonsense or missense mutations in BRCA1 and other genes // Nat. Genet.-2001 .-V.27.-P.55-58.

281. Lubinski J., Gorski B., Huzarski T., et al. BRCAl-positive breast cancers in young women from Poland // Breast Cancer Res. Treat. In press.-2006.

282. Loginova A.N., Pospekhova N.I., Lyubchenko L.N., et al. Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families // Bull.Exp.Biol.Med.-2003.-V.136.-P.276-278.

283. Loman N., Johannsson O., Bendahl P., et.al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 and BRCA2 mutations or unknown susceptibility genes. // Cancer.-1998.-V.83.-P.310-319.

284. Loman N., Johannsson O., Kristoffersson U., et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population based cancer // J. Natl. Cancer Inst.-2001.-V.93.-P.1188-1189.

285. Lynch H.T., Bewtra C., Lynch J.F. Familial ovarian cancer: clinical nuances //Am J. Med.-1986.-V.81.-P. 1073-1076.

286. Lynch H.T., Watson P., Bewtra C., et al. Hereditary ovarian cancer. Heterogenity in age at diagnosis // Cancer.-1991.-V.67.-P.1460-1466.

287. Lynch H.T., Shaw T.G., Lynch J.F. Inherited predisposition to cancer: a historical overview //Am J.Med.Genet.-2004.-V.129.-P.5-22.

288. Lynch H.T., Smyrk T.C., Watson P., et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer an updated review // Gastroenerology.-1993.-V.104.-P.1535-1549.

289. Lynch H.T., Kimberling W., Albano W., et al. Hereditary nonpolyposis colorectal cancer (Lynch syndrome 1 and 2): I clinical description of resource // Cancer.-1985.-V.56. P.934.

290. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark and Finland // N.Engl.J.Med.-2000.-V.343.-P.78-85.

291. Lynch H.T., Marcus J., Watson P., et al. Familial and Hereditary Breast Cancer // Endocrine-Related Cancer.-1989.-P.9-15.

292. Mackley S.E., Creasman W.T. Ovarian cancer screening // J.Clin. Oncol. -1995. -V13.-P. 783 793.

293. Magnusson C.M., Persson I.R., Baron J.A., Ekbom A., et al. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years // Int.J.Cancer.-1999.-V.80.-P.231-236.

294. Magnusson C.M., Colditz G., Rosner B. Association of family history and other risk factors with breast cancer risk (Sweden) // Cancer Causes Control.-1998.-V.9.-P.259-267.

295. Malone K.E., Daling J.R., Thompson J.D., et al. BRCA1 mutations and breast cancer in the general population analyses in women before age 35 years and in women before age 45 years with first-degree family history // JAMA.-1998.-V.922-929.

296. Malone K.E., Daling J.R., Neal C., et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases // Cancer.-2000.-V.88.-P. 1393-1402.

297. Manolio T.A., Bailey-Wilson J.E., Collins E.S. Genes, environment and the value of prospective cohort studies // Nat.Rev.Genet.-2006.-V.7.-P.35-50.

298. Margolin S., Werelius B., Fornander T., Lindblom A. BRCA1 mutations in a population-based study of breast cancer in Stockholm Country // 2007.-Genet.Test.-1004.-V.8.-P. 127-132.

299. Marcus J.N., Watson P., Page D., et al. Hereditary breast cancer pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage // Cancer.-1996.-V.77.-P.66.

300. Martin A.M., Blackwood M.A., Antin-Ozerkis D., et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic // J.Clin.Oncol.-2001.-V.19.-P.2247-2253.

301. Mateus P., Sigurdson A.J., Doody M.M., et al. CHEK2*1100delC and female breast cancer in United States // Int. J. Cancer.-2004.-P.112.-P.541-543.

302. Matias Guiu X., Prat J. Molecular pathology of ovarian carcinomas // Virchows. Arch.-1998.-V.59. -P.297-304.

303. Martinez-Ferrandis J.I., Vega A., Chirivella I., et al. Mutational analysis of BRCA1 and BRCA2 in mediterranen Spanish women with early-onset breast cancer: Identification of three novel pathogenetic mutations // Hum. Mutat. -2003. -V.22.-P.417-418.

304. Matsuoka S., Rotman G., Ogawa A., Shiloh Y.,et al. Ataxia telangiectasia-mutated phosphorylates Chek2 in vivo and in vitro// Proc. Natl. Acad.Sc.-USA.-2000.-V.97.P. 10389-10394.

305. Matsuoka S., Huang M., Elledge S J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase // Scince.-1998.-V.282.-P.1893-1897.

306. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes // Hum. Mutat.-2005.-V.25.-P.415-422.

307. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low penetrance susceptibility to breast cancer duo to CHEK2:!:1100delC in noncarriers of BRCAlor BRCA2 mutations // Nature.Genet.-2002.-V.31.-P.55-59.

308. Menkiszak J., Gronwald J., Gorski B., et al. Hereditary ovarian cancer in Poland//Int. J. Cancer.-2003.-V.106.-P.942-945.

309. Merajver S.D., Pham T.M., Caduff R.E., Chen M., Poy E.L., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors // Nature Genet.-1995.-V.9.-P.439-443.

310. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation // N. Engl. J. Med.- 2001.-V.345.-P.159-164.

311. Meijers-Heijboer H., Wijnen J., Vasen H., et al. The CHEK2*1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype // Am.J.Hum.Genet.-2003.-V.72.-P.1308-1314.

312. Meijers-Heijboer H., van den Ouweland A., Klijin J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations // Nat.Genet.-2002.-V.31.-P.55-59.

313. Meijers-Heijboer H. CHEK281100delC is a low penetrance familial breast cancer susceptibility allele thet does not elevate breast cancer in BRCA1/2 mutation carriers // Nat.Genet.-2002.-V.31.-P.55-59.

314. Menkiszak J., Gronwald J., Gorski B., et al. Clinical Features of Familial Ovarian Cancer Lacking Mutations in BRCA1 or BRCA2 // Gynecological Oncology.

315. Menkiszak J., Jakubowska A., Gronwald J., et al. Hereditary ovarian cancer: summary of 5 years of experience // Ginecol.Pol.-1998.-V.69.-P.283-287.

316. Miki Y., Swensen J., Shattuck-E. D., Futreal P.A., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 // Science.-1992.-V.266.-P.66-67.

317. Moore K.H., Bertman K.A., Gomes R.R., et al. Sex hormone-binding globulin mRNA in human breast cancer detection in cell lines and tumor samples//J. Steroid. Biochem. Mol. Biol. -1996. -V.59. -P.297-304.

318. Moore M.M. The role of specialized genetic counceling for the patient at risk for breast cancer // Cancer Control. JMCC.-1998.-V.5.-P.1250-1252.

319. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer // Am.J.Hum.Genet.-2000.-V.66.-P. 1259.

320. MonteiroA., August A., Hanafusa H. Common BRCA1 variants and transcriptional activation // Am Hum Genet.-1997.-V.61.-P.761-762.

321. Muir C., Waterhouse J.A., Mack T., et al. editors. Cancer Incidence in Five Continents Volume 5 // Lyon, France: IARC Scientific Publications.-1987.

322. Muto M.G., Cramer D.W., Tangir L., et al. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and match population controls // Cancer.-V.1996.-P.1250-1252.

323. Narod S.A., Tonin P., Lynch H., Watson P., et al. Histology of BRCA1-associated ovarian tumors // Lancet.-1994.-V.343.-P.236.

324. Narod S.A., Dube M.P., Klijn J., Lubinski J., et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutations Carriers // J. Natl. Cancer Inst.-2002.V.4.-P. 1773-1779.

325. Narod S.A., Ford D., Devilee P., Barkardottir R.B., et al. An evaluation of genetic heterogeneity, in 145 breast ovarian cancer families // Am J. Hum.Genet.-1995.-V.56.-P.254-264.

326. Narod S.A., Risch H., Moslehi R., et.al. Oral contraceptives and the risk of hereditary ovarian cancer // N.Engl.J.Med.-1998.-V.339.-P.424-428.

327. Narod S.A., Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer // Curr.Opin.Obstet.Gynecol.-2002.-V.14.-P. 19-26.

328. Nelson H.D., Huffman L.H., Fu R., et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for U.S. preventive services task force // Ann Intern Med.-2005.-V.143.-P.362-379.

329. Neuhausen S., Dunning A., Steele L., et al. Role of CHEK2 *1100delC in unseleeted series of non-BRCAl/2 male breast cancers // Int.J.Cancer.-2004.-V. 108.-P.477-478.

330. Nevalinna H. CHEK2 gene // BCLC. Familial cancer.-2003.-V.2.-P.186.

331. Nevalinna H. The Finnish population structure. A genetic and genealogical study // Hereditas.-1972.-V.71.-P. 195-236.

332. Newman B.C., Austin M.A., Lee M., King M. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families //Proc. Natl. Acad. Sci. USA.-1998.-V.85.-P.3044-3048.

333. Newman B.C., Millikan R.C., King M.C. Genetic epidemiology of breast and ovarian cancers // Epidemiol. Rev. -1997.-V.19.- P.69-79.

334. Nilsson A. Iimmigration and emmigration in the postwar period // Statistics Sweden: Demographic Reports.-2004.

335. Ohayon T., Gal I., Baruch R.G., Szabo C., et al. CHEK2*1100delC and male breast cancer risk in Israel // Int.J.Cancer.-2004.-V.108.-P.479-480.

336. Offit K., Pierce H., Kirchhoff T., et al. Frequency of CHEK2*1 lOOdelC in New York breast cancer cases and controls // BMC Med.Genet.-2003.-V.4.-P.l-4.

337. Oldenburg R.A., Kroeze -Jansema K., Kraan J., et al. The CHEK2* 1 lOOdelC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families // Cancer Res.-2003.-V.63.-P.8153-8157.

338. Osin P., Crook T., Powles T., Peto J., Gusterson B. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers // Lancet.-1998.-V.351.-P.1487.

339. Oszurek O., Gorski B., Gronwald J.et al. Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families // Clin.Genet.-2001.-V.60.-P.470-471.

340. Oldenburg R.A., Kroeze-Jansema K., Kraan J., et al. The CHEK2 1 lOOdelC variant acts as breast cancer risk modifier in non-BRCAl/BRCA2 multiple-case families // Cancer Res.-2003.-V.63.-P.8153-8157.

341. Ozols R., F., Rubin S.C., Dembo A.J., et al. Epithelial ovarian cancer // Principles and practice of gynecologic oncology. Eds. W.J. Hoskins et al.-Philadelphia J.P.Lippin-cott.-1992.-P.731.

342. Pal T., Permuth-Wey J., Betts J.A., et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases // Cancer.-2005.-V. 104.-P.2807-2816.

343. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B., editors. Cancer Incidence in Five Continents Volume 8 // Lyon, France: IARC Scientific Publications.-2002.

344. Parmigiani G., Berry D., Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 // Am. J. Hum. Genet .-1998.-V.62.-P. 145-158.

345. Peelen T., van Vliet M., Petrij-Bosch A., et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families // Am J. Hum.Genet.-1997.-V.60.-P. 1041-1049.

346. PerkowskaM., Brozek I., Wysocka B., et al. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from Northeastern Poland // Hum. Mutat. -2004. -V.21.-P.553-554.

347. Pérou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumors // Nature.-2000.-V.406, P.747-752.

348. Peto J., Collins N., Barfoot R., et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer // J. Natl. Cancer Inst.-1999.-V.91.-P.0943-949.

349. Pharoah P.D., Antoniou A., Bobrow M., et al. Polygenic susceptibility to breast cancer and implications for prevention // Nat.Genet.-2002.-V.31.-P.33-36.

350. Pharoah P.D., Dunning A.M., Ponder B.A., et al. Association studies for finding cancer-susceptibility genetic variants // Nat. Rev. Cancer.-2004.-V.4.-P.850-860.

351. Piver M.S., Barlow J.J., Sawger D. Familial ovarian cancer. Increasing in frequency // Obstet Gynecol.-1982.-V.60.-P.397-399.

352. Piver M.S., Baker T.R., Piedmonte M., et al. Epidemiology and etiology of ovarian cancer// Cancer.Semin.Oncol.-1991.-V.18.-P.177.

353. Piver M.S. Prophylactic oophorectomy and ovarian cancer mortality // Philadelphia: J.B. Lippincott Company.-1992.-P.l-10.

354. Plummer S.J., Anton-Culver H., Webster L., et al. Detection of BRCA1 mutations by the protein truncation test // Hum. Mol. Genet. 1995. -V.10. -P.1989-1991.

355. Pohlreich P., Stribrana J., Kleibl Z., Zikan M., et al. Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic //Med. Princ. Pract.-2003.-V.12.-P.23-29.

356. Ponder B. Genetic testing for cancer risk // Science.-1997.-V.278.-P. 10501054.

357. Pukkala E., Kesminiene A., Poliakov S., et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident // Int. J. Cancer.-2006.-V.119.-P.651-658.

358. Purdi D., Green A., Bain C., et al. Reproductive and other factors and risk of epithelial ovarian cancer // Int.J.Cancer.-1995.-V.62.-P.678-684.

359. Rahman N., Stratton M.R. The genetics of breast cancer susceptibility // An. Rey Genet.-1998.-V.57.-P.95-121.

360. Rahman N., Teare M.D., Seal S., et al. Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8pl2-p22 // Oncogene.-2000.-V. 19.-P.4170-4173.

361. Ramus S.J., Kote-Jaral Z., Friedman L.S., et al. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer // Am Hum. Genet.-1997.-V.60.-P. 1242-1246.

362. Ramus S.J., Friedman L.S., Gayther S.A., et al. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2 // Nat. Genet.-1997.-V.15.-P.14-15.

363. Rebbeck T.R., Couch F.G., Kant J., Calzone K., et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2 // Am J. Hum. Genet.-V.59. -P.547-553.

364. Rhei E., Bogomolniy F., Federice M.G., et al. Molecular genetic characterization of BRCA1 and BRCA2-linked hereditary ovarian cancer // Cancer.Res.-1998.-V.58.-P.3193-3196.

365. Risch H.A., Laughlin J.L., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer // Am J.Hum.Genet.-1994.-V.7.-P.700-710.

366. Risinger J.I., Berchuck A., Kohler M.F. et al. Mutations of the E-cad. gene in human gynecologic cancers // Nature.Genet.-1994.-V.7.-P.98-102.

367. Roa B.B., Boyd A.A., Volcik K., Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 // Nature Genet.-1996.-V.14.-P. 185-187.

368. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 // N.Engl. J.Med.-1996.-V.335.-P. 1413-1416.

369. Rustin G.J.S., Nelstrop A.E., Bentzen S.M., et al. Use of tumor markers in monitoring the ovarian cancer // Annals of Oncology.-1999.-V.10.-P.21-27.

370. Sato T., Akiyama F., Sakamoto G., et.al. Accumulation of genetic alterations and progression of primary breast cancer // Cancer. Res. 1991. -V.51.- P.-5794.

371. Santarosa M., Viel A., Dolcetti R., et al. Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer // Int. J. Cancer.-1998.-V.78.-P.581-586.

372. Santarosa M., Dolcetti R., Crivellary D., et al. BRCA1 and BRCA2 genes: Role in hereditary breast and ovarian cancer in Italy // Int.J.Cancer.-1999.-V.83.-P.5-9.

373. Sarantaus L., Auranen A., Nevanlinna H. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families // Int. J. Oncol.-V.18.-P.831-835.

374. Schrager C.A., Schneider D., Gruener A.C., Tsou H.C., Peacocke M. Clinical and pathological features of breast disease in Cowden is syndrome an underreccognized syndrome with an increased risk of breast cancer // Hum.Pathol.-1998.-V.29.-P.47-53.

375. Schapira M.M., Matchar D., Young M.J. The effectiveness of ovarian cancer screening. A decision analysis model // Ann.Intern.Med.-1993.-V.118.-№ll.-P.838-843.

376. Schutte M., Seal S., Barfoot R., et al. Variants in CHEK2 other then 1 lOOdelC do not make a major contribution to breast cancer susceptibility // Am J. Hum Genet.-2003.-V.72.-1023-1028.

377. Schwartz P.E. Is early detection of ovarian cancer possible // Ann.Med.-1995. V.27.-P.519-528.

378. Seitz S., Rohde K., Bender E., Nothnagel A., ET AL. Strong indication for a breast cancer susceptibility gene on chromosome 8pl2-p22: linkage analysis in German breast cancer families //Oncogene.-1997.-V.14.-P.741-743.

379. Seal S., Barfoot R., Jayatilake H., et al. Evaluation of Fanconi Anemia in familial breast cancer // BCLC Familial cancer.-2003.-V.2.-P.212-213.

380. Serov S.F., Scully R.E., Sobin L.H. International histologic classification and staging of tumors: no 9 histologic typing of ovarian tumors // Geneva World Health Organization.-1973.

381. Serova O.M., Mazoyer S., Puget N., Dubois V., et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer susceptibility genes // Am Hum.Genet.-1997.-V.60.-P.486-495.

382. Shaag A., Walsh T., Renbaum P., Kirchhoff T., et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Aslikenazi Jewish population // Hum.Mol.Genet.-2005.-V.14.-P.555-563.

383. Shaw P.A., Pepe M.S., Alonzo T.A., et al. Methods for Assessing improvement in specificity when a Biomarker // Stat, of Biopharm. Res.2002. -12c.

384. Stefanie S., Jeffrey M., Per Eystein L., et al. Genomics-Based Prognosis and Therapeutic Prediction in Breast Cancer // J. Nat. Com. Cancer Net.-2005.-V.3.-P.291-300.

385. Shiao Y.H. The von Hippel-Lindau gene and protein tumorigenesis and angiogenesis a potential target for therapeutic designs // Curr.Med.Chem.2003.-V.10.-P.2461-2470.

386. Shelling A.N., Cooke I.E. Ganesan T.S. The genetic analysis of ovarian cancer // Br. J.Cancer.-1995.-V.72.-P.512-527.

387. Simard J., Tonin P., Durocher F., Morgan K., et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families // Nature Genet.-1994.-V.8.-P.71-76.

388. Smith S. A., DiCioccio R. A., Struewing J.P., Easton D.F., et al. Localisation of the breast-ovarian susceptibility gene (BRCA1) on 17ql2-21 to an interval of <lcM // Genes Chrom.Cancer.-1994.-V.10.-P.71-76.

389. Smith J.P., Rutledge F. Advances in chemotherapy for gynecologic oophorectomy in inherited breast/ovarian cancer families: Abstract // Am.J.Hum.Genet.-1994.-№55.-P.497.

390. Smith J.P., Easton D.F., Evans D.G., et al. Allele losses in the region 17ql2-21 in familial breast and ovarian cancer involve the wil-type chromosome // Nat. Genet.-1992.-V.2.-P. 128-131.

391. Sobol H., Birnbaun D., Eisinger F. Evidence for a third breast-cancer susceptibility gene // Lancet.-1994.-V.344.-P.l 151-1152.

392. Sodha N., Wilson C., Bullock S.L., et al. Analysis of familial male breast cancer for germline mutations in CHEK2 // Cancer Lett.-2004.-V.215.-P.187-189.

393. Sokolenko A.P., Rozanov M.E., Mitiushkina N.V., et al. Founder mutations in early-onset, familial breast cancer patients from Russia // Fam.Cancer.-2007.-V.6.-P.281-286.

394. Sommer S.S., Jiang Z., Feng J., et al. ATM missense mutations are frequent in patients with breast cancer // Cancer .Genet.Cytogenet.-2003.-V.145.-P.l 15-120.

395. Stoppa-Lyonnet D., Ansquer Y., Dreyfus H., et al. Familial invasive breast cancer: Worse Outcome Related to BRCA1 mutations //JCO.-2000.-V. 18.-P.4053-4059.

396. Stoppa-Lyonnet D., Hall J., Janin N., et al. Low-penetrance genes heterozygote ATM mutation carriers and breast cancer risk // BCLC. Familial. Cancer.- 2003.-V.18.- P.4053-4059.

397. Stoppa-Lyonnet D., Laurent-Puig P., Essioux L., et al. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic // Am J. Hum.Genet.-1997.-V.60.-P. 1021-1030.

398. Struewing J.P., Hartge P., Warcholder S., Bacer S.M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews // N.Engl.Med.-1997.-V.336.-P.1401-1408.

399. Sulliva A., Yuille M., Repellin C., et al. Concomitant inactivation of p53 and CHEK2 in breast cancer // Oncogene.-2002.-V.21.-P. 1316-1324.

400. Szabo C., King M. Population genetics of BRCA1 and BRCA2 // Am J.Hum.Genet.-1997.-V.60.-P. 1013-1020.

401. Syrjakoski K., Kuukasjarvi T., Auvinen A., et al. Chek2*1100delC is not a risk factor for male breast cancer population // Int.J.Cancer.-2004.-V.108.-P.475-476.

402. Szabo C., Neuhausen S., Devilee P., et al. BRCA1 founder mutations population genetics and genome evolution // BCLC. Familial Cancer. -2003.-V.2.- P.177-178.

403. Takahashi H., Behbakt K., et.al. Mutation analysis of BRCA1 gene in ovarian cancers // Cancer.Res.-1995.-V.55.-P.2998-3002.

404. Takahashi H. TMF and cancer therapy-induced apoptosis: potentiate on by inhibition of NF-Rappa //Science.-1996.-V.274.-P.784-787.

405. The WHO Collaborftive Study of Neoplasia and Steroid Contraceptives // Int.J.Epidemiol.-1989.-V.18.-P.538.

406. Tewari K., Cappuccini F., Disaia P., et al. Malignant germ cell tumors of the ovary//Obstet. Gynecol.-2000.-V.95.-P.128.

407. Tereshenko I.V., Basham V.M., Ponder B.A., et al. BRCA1 and BRCA2 mutations in Russian familial breast cancer // Hum.Mut.-2002.-V.476.-P.l-3.

408. Terry P., Wolk A., Magnusson C. Brassica vegetables and breast cancer risk //Jama.-2001.-V.285.-P.2975-2977.

409. The CHEK2 Breast Cancer Case-Control Consortium. Chek2 llOOdelC and susceptibility to breast cancer: a collaborative analysis involving 19,860 breast cancer and 9,065 controls from 10 studies // Am Hum.Genet.-2004.-V.74.-P.1182.

410. Thompson D., Seal S., Schutte M., et al. A multicenter study of cancer incidence in CHEK2* llOOdelC mutation carriers // Cancer Epidem.Biomark.Prev.-2006.-V. 15 .-P.2542-2545.

411. Thompson D., Easton D.F. The genetic epidemiology of breast cancer genes //J. Mammary Gland.Biol.Neoplasia.-2004.-V.9.-P.221-236.

412. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers // J. Natl. Caner Inst.-2002.-V.94.-P.1358-1365.

413. Thompson D., Easton D.F. Variation in BRCA1 cancer risks by mutation position // Cancer Epidemiol. Biomerkers Prev.-2002.-V.l 1.-P.329-336.

414. Thompson D., Duedal S., Kirner J., et al. Cancer risks and mortality in heterozygous ATM carriers // J. Natl. Cancer Inst.-2005.-V.97.-P.813-822.

415. Thorlacius S., Struewing J., Hartge P., et al. Population -based study of risk breast cancer BRCA2 mutation // Lancet.-1998.-V.352.-V.352.-P.1337.

416. Thorlacius S., Olafsdottir G., Tryggvadottir L., et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes // Nat.Genet.-1996.-V.13.-P.117-119.

417. Tillib S.V., Strizhkov B.A., Mirzabekov A.D. Integration of multiple PCR amplifications and DNA mutation analyses by using oligonucleotide microchip // Anal.Biochem.-V.292.-P. 155-160.

418. Trimble E.L., Trimble C.L. Epithelial ovarian tumors of low malignant potential // Cancer of the ovary // Ny: Raven. Press. -1993. -V.18.- P.538.

419. Tortolero-Luna G., Mithell M.F. The epidemiology of ovarian cancer // J. of cell. Biochemistry Supplem. -1995. -V.230.- P.200-207.

420. Ursin G., London S., et al. A pilot Study of urinary estrogen metabolits in post menopausal women with and without breast cancer // Environ Health Persp.-1997.-V.105.-P.601-605.

421. Ursin G., Heuder S., Harle R.W., et al. Does oral contraceptive use increase the risk of Breast cancer more in women with BRCA1/BRCA2 mutations than in other women // Cancer Res.-1997.-V.57.-P.3678-3681.

422. Vahteristo P., Eerola H., Tomminen A., et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families // Br. J. Cancer.-2001.-V.84.-P.704-708.

423. Vahteristo P., Bartkova J., Eerola H., et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer // Am J. Hum. Genet. -2002. -V.71.-P.432 -438.

424. Venkitaraman A. Breast cancer genes and DNA repair // Science.-1999.-V.286.-P.1100-1102.

425. Venkitaraman A. Cancer susceptibility and the functions of BRCA1 and BRCA2 // Cell.-2002.-V. 108.-P. 171-182.

426. Verhoog L. Brekelmans C., Seynaeve C., et al. Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1 // Lancet.-1998.-V.351.-P.316-321.

427. Veronesi A., de Giacomi C., Magri M.D., et al. Familial breast cancer: characteristics and outcome of BRCA1 2 positive and negative cases // BMC Cancer.-2005.-V.5.-P.70-76.

428. Wagner T.M., Moslinger R.A., Muhr D., et al. BRCAl-related breast cancer in Austrian breast and ovarian cancer families specific BRCA1 mutations and pathological characteristics // Int. J. Cancer.-1998.-V.77.-P.354-360.

429. Walsh T., Casadei S., Coats K.H., et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TR53 in families at high risk of breast cancer // JAMA.-2006.-P.295.-P. 1379-1388.

430. Walworth N.C. Cell-cycle checkpoint kinases: checking in on the cell cycle // Curr. Opin. Cell. Biol.-2000.-V.14.-P.697-704.

431. Warner E., Foulkes W., Goodwin P., Meschino W., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer // J. Natl. Cancer Inst.-1999.-V.91.-P.1241-1249.

432. Warner E., Causer P.A. MRI surveillance for hereditary breast-cancer risk // Lancet.-2005.-V.365.-P. 1747-1749.

433. Warthin A.S. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigem.-1992.-V. 136.-P. 1184-1203.

434. Waterhouse J.A., Muir C., Correa P., et al. Cancer Incidence in Five Continents Volume 3 // Lyon, France: IARC Scientific Publications.-1976.

435. Waterhouse J.A., Muir C., Shanmugaratnam K., Powell J., et al. Cancer Incidence in Five Continents Volume 4 // Lyon, France: IARC Scientific Publications.-1982.

436. Weber B.L., Nathanson K.L. Low penetrance genes associated with increased risk of breast cancer // Eur. J. Cancer.-2000.-V.36.-P. 1193-1199.

437. Weinert T. Chekpoints controls that ensure the order of cell cycle events // Science.-1989.-V.246.-P.629-634.

438. Weinert T. Yeast checkpoint controls and relevance to cancer // Cancer Surv.-1997.-V.29.-P. 109-132.

439. Weischer M., Bojesen S.E., Tybjaerg-Hansen A., et al. Increased risk of breast cancer associated with CHEK2*1100delC // J.ciin.0ncol.-2007.-V.41.-P.57-63.

440. Whittemore A. S., Gong G., et al. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer results from three U.S. population-based case-control studies of ovarian cancer // Am J.Hum.Genet.-1997.-V.60.-496-504.

441. Whittemore A. S. The risk of ovarian cancer after treatment for infertility // N.Engl.J.Med.-1994.-V.331.-P.805.

442. Whitechouse P.A., Sharma S., Neall M.H., et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pretreated recurrent ovarian carcinoma // BMC Cancer.-2003.-V.3.-P.19.

443. WHO. Pathology and Genetics: Tumors of the Breast and Female Genital Organs // Lyon: IARC Press.-2003.

444. Weber B.L. Localization of BRCA1 and a splice variant identifies the nuclear localization signal // Mol.Cell.Biol.-1997.-V.17.-P.444-452.

445. Williams L.H., Choong D., Johnson S.A., et al. Genetic and analysis of CHEK2 in sporadic breast, colon, and ovarian cancer // Clin.Cancer.Res.-2006.-V.1.-P.72.

446. Woodward A.M., Davis T.A., Silva A.G., et al. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected // J. Med. Genet.-2005.-V.42.-P.42.

447. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2 // Nature.-1995.-V.378.-P.789-792.

448. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13 // Science.-1994.-V.265.-P.2088-2090.

449. Welcsh P., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer//Hum. Mol. Genet.-2001.-V.10.-P.705-713.

450. Wu X., Webster S.P., Chen J. Characterization of tumor-associated CHE2 mutations // J.Biol.Chem.-2001.-V.276.-P.2971-2974.

451. Yancik R. Ovarian cancer. Age contrasts in incidence histology, disease stage at diagnosis, and mortality // J.Cancer.-1993.-V.71.-P.517.

452. Yancik R. Population aging and cancer // J.Cancer.-2005. V.l 1.-P.-437-441.